$CELC

BAKER BROS. ADVISORS LP sold $317.8M of CELC (indirect holdings)

BAKER BROS. ADVISORS LP sold 3,100,000 indirectly-held shares of Celcuity Inc. (CELC) at $102.50 ($317.75M total) across 2 trades on 2026-07-14.

Original reporting
SEC EDGAR · BAKER BROS. ADVISORS LP
Published Jul 16, 2026, 9:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 9:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CELC
Neutral
medium confidence
Mentioned
$CELC
Relevance
9/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CELCNeutralLow
01

Why it matters

A reported open-market sale of 3.1M shares at $102.50 totals about $317.75M, which can influence short-term sentiment but does not, by itself, change company fundamentals.

02

Market read

Traders may monitor CELC for follow-on selling signals, but the text provides no new operational catalyst or guidance change.

03

What to watch

No 10b5-1 plan is stated, but the filing does not provide intent, cost basis, or whether other related entities increased/decreased holdings around the same time.

Relevance 9/10Novelty 5/10Timing: after-hours/filing update on 2026-07-16 for a 2026-07-14 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Celcuity Inc. (CELC) reported by Baker Bros. Advisors LP as an indirect holding.

Company-level read

Ticker impact

$CELCNeutralMedium confidence
Context

Celcuity (CELC) disclosed a $317.75M indirect open-market sale by Baker Bros. Advisors on 3.1M shares at $102.50.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any impact is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider transaction disclosure with no 10b5-1 plan and no accompanying company-specific operational or guidance change in the text.

Market effects

Limited sector read-through because the disclosure is company-specific and does not cite industry/regulatory developments.

None indicated; this is a US-listed issuer Form 4.

None indicated.

Counterpoint

The sale is indirect and may reflect portfolio rebalancing or tax/liquidity needs rather than a bearish view on Celcuity’s fundamentals.

Key entities

  • Celcuity Inc.

    Subject of the Form 4 disclosure; shares sold indirectly by Baker Bros. Advisors LP.

  • Baker Bros. Advisors LP

    Reported the indirect open-market sale of 3,100,000 CELC shares.

  • SEC Form 4

    Primary-source disclosure of insider transaction details, filed 2026-07-16.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CELCMedAI 8/10

Celcuity reports phase 1b prostate cancer trial results

Celcuity Inc. (CELC) reported Phase 1b/2 trial results for gedatolisib combined with darolutamide in metastatic castration-resistant prostate cancer. The study showed median radiographic progression-free survival of 15.7 months for patients who received prior abiraterone and 9.1 months for those who received prior enzalutamide. The company plans to begin the Phase 2 portion of the study in the first half of 2027.

High

Celcuity Shares Climb Nearly 8% as Cantor Fitzgerald Backs Breast Cancer Drug Maker Ahead of Key ESMO Data

Celcuity Inc. shares rose 7.78% after Cantor Fitzgerald initiated coverage with an overweight rating and a $140 price target, citing growth potential of its breast cancer drug, Revtorpyk. The company will present key clinical data at the ESMO Congress this weekend. Analysts are bullish, with price targets ranging from $130 to $177, despite a 50% stock decline over six months.

$CELCMed

How REVTORPYK Launch Will Impact Celcuity (CELC) Investors

Celcuity (CELC) launched REVTORPYK in the US for certain breast cancer patients and filed an FDA application to expand its use. The company is investing in access infrastructure, and investors will watch early prescription trends and FDA review progress. Celcuity's consensus revenue and earnings forecasts for 2029 are US$817.9 million and US$267.5 million, respectively, up from current losses. The appointment of David W. Gryska to the board may impact financial oversight and execution.